1,https://www.reuters.com/article/brief-bio-rad-laboratories-estimates-q2/brief-bio-rad-laboratories-estimates-q2-currency-neutral-sales-to-decline-by-5-to-10-idUSFWN2D30RF,2020-05-21T21:45:18Z,BRIEF-Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%,May 21 (Reuters) - Bio Rad Laboratories Inc:,* BIO RAD LABORATORIES SAYS IT EXPECTS Q2 2020 YEAR-OVER-YEAR CURRENCY NEUTRAL SALES MAY DECLINE BY 5 TO 10 PERCENT - SEC FILING Source text: (bit.ly/3glQfJ0) Further company coverage:
2,https://www.reuters.com/article/brief-bio-rad-reports-q1-non-gaap-earnin/brief-bio-rad-reports-q1-non-gaap-earnings-per-share-1-91-idUSASA00O8E,2020-05-06T21:13:47Z,BRIEF-Bio-Rad Reports Q1 Non-GAAP Earnings Per Share $1.91,May 6 (Reuters) - Bio Rad Laboratories Inc:,* Q1 EARNINGS PER SHARE ESTIMATE $1.57 -- REFINITIV IBES DATA,* WITHDRAWING OUR PREVIOUSLY ISSUED ANNUAL GUIDANCE FOR THIS YEAR Source text for Eikon: Further company coverage:
3,https://www.reuters.com/article/brief-bio-rad-receives-fda-emergency-use/brief-bio-rad-receives-fda-emergency-use-authorization-for-droplet-digital-pcr-sars-cov-2-test-kit-idUSFWN2CM12R,2020-05-05T00:18:12Z,BRIEF-Bio-Rad Receives FDA Emergency Use Authorization For Droplet Digital Pcr Sars-Cov-2 Test Kit,May 4 (Reuters) - Bio Rad Laboratories Inc:,* BIO-RAD RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR DROPLET DIGITAL PCR SARS-COV-2 TEST KIT Source text for Eikon: Further company coverage:
4,https://www.reuters.com/article/brief-bio-rad-begins-shipping-covid-19-a/brief-bio-rad-begins-shipping-covid-19-antibody-test-idUSFWN2C90SL,2020-04-21T12:47:02Z,BRIEF-Bio-Rad Begins Shipping COVID-19 Antibody Test,April 21 (Reuters) - Bio Rad Laboratories Inc:,* BIO-RAD BEGINS SHIPPING SARS-COV-2 (COVID-19) ANTIBODY TEST THAT OFFERS MORE THAN 99 PERCENT SPECIFICITY AND 98 PERCENT SENSITIVITY Source text for Eikon: Further company coverage:
5,https://www.reuters.com/article/brief-bio-rad-acquires-celsee-inc/brief-bio-rad-acquires-celsee-inc-idUSASA00KD1,2020-04-09T12:31:40Z,BRIEF-Bio-Rad Acquires Celsee Inc,April 9 (Reuters) - Bio Rad Laboratories Inc:,"* BIO-RAD ACQUIRES CELSEE, INC., A SINGLE-CELL ANALYSIS SOLUTIONS PROVIDER",* BIO RAD LABORATORIES INC - TERMS OF ACQUISITION WERE NOT DISCLOSED Source text for Eikon: Further company coverage:
6,https://www.reuters.com/article/brief-bio-rad-to-launch-serology-assay-t/brief-bio-rad-to-launch-serology-assay-to-detect-coronavirus-antibodies-idUSFWN2BV0O5,2020-04-07T13:02:49Z,BRIEF-Bio-Rad To Launch Serology Assay To Detect Coronavirus Antibodies,April 7 (Reuters) - Bio Rad Laboratories Inc:,* BIO-RAD ANNOUNCES THE LAUNCH OF A SEROLOGY ASSAY TO DETECT CORONAVIRUS (COVID-19) ANTIBODIES,* BIO RAD LABORATORIES INC - PLANS TO OFFER IMMUNOASSAY KIT GLOBALLY,"* BIO RAD LABORATORIES INC - IN UNITED STATES, CO INTENDS TO USE FDA’S EMERGENCY USE AUTHORIZATION PROCESS TO EXPEDITE U.S. AVAILABILITY Source text for Eikon: Further company coverage:"
7,https://www.reuters.com/article/brief-biodesix-partners-with-bio-rad-to/brief-biodesix-partners-with-bio-rad-to-bring-emergency-use-authorization-covid-19-ddpcr-test-to-the-u-s-idUSFWN2BD0DH,2020-03-20T11:03:20Z,BRIEF-Biodesix Partners With Bio-Rad To Bring Emergency Use Authorization Covid-19 Ddpcr Test To The U.S.,March 20 (Reuters) - Bio Rad Laboratories Inc:,* BIODESIX PARTNERS WITH BIO-RAD TO BRING EMERGENCY USE AUTHORIZATION (EUA) COVID-19 DDPCR™ TEST TO THE U.S.,* BIO RAD LABORATORIES INC - DATA SHOW DROPLET DIGITAL PCR TEST CAN DETECT COVID-19 WITH GREATER SENSITIVITY AND PRECISION,* BIO RAD LABORATORIES INC - BIODESIX AND BIO-RAD ARE WORKING TO GAIN EUA APPROVAL TO ALLOW BIODESIX TO BEGIN TESTING IN U.S. FOLLOWING THAT APPROVAL Source text for Eikon: Further company coverage:
8,https://www.reuters.com/article/brief-bio-rad-partners-with-testing-labs/brief-bio-rad-partners-with-testing-labs-worldwide-to-support-covid-19-testing-idUSFWN2BB1IR,2020-03-18T23:37:37Z,BRIEF-Bio-Rad Partners With Testing Labs Worldwide To Support Covid-19 Testing,March 18 (Reuters) - Bio Rad Laboratories Inc:,* BIO-RAD PARTNERS WITH TESTING LABS WORLDWIDE TO SUPPORT COVID-19 TESTING Source text for Eikon: Further company coverage:
9,https://www.reuters.com/article/idUSASB01WI1,2019-08-27T21:38:15Z,CORRECTED-(OFFICIAL)-BRIEF-Bio-Rad Posts Q2 EPS Of $19.86 (Aug. 1),"(Corrects Q2 non-GAAP EPS in second bullet to $1.49, from $1.57, as the company’s prior press release contained a $3.37 million error related to legal matters)",Aug 27 (Reuters) - Bio Rad Laboratories Inc:,* Q2 SALES $572.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $566.2 MILLION,* Q2 EARNINGS PER SHARE ESTIMATE $1.34 -- REFINITIV IBES DATA,"* FOR FY 2019, COMPANY CONTINUES TO ANTICIPATE CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 4.0 TO 4.5% Source text: (bit.ly/2ztrkyE) Further company coverage:"
10,https://www.reuters.com/article/brief-bio-rad-q1-earnings-per-share-2177/brief-bio-rad-q1-earnings-per-share-21-77-idUSASC0A0QO,2018-05-08T21:42:45Z,BRIEF-Bio-Rad Q1 Earnings Per Share $21.77,May 8 (Reuters) - Bio Rad Laboratories Inc:,* Q1 SALES $551.5 MILLION VERSUS I/B/E/S VIEW $527.2 MILLION,* Q1 EARNINGS PER SHARE VIEW $1.07 -- THOMSON REUTERS I/B/E/S,"* BIO RAD LABORATORIES - FOR 2018, CONTINUES TO ANTICIPATE CURRENCY-NEUTRAL REVENUE GROWTH OF APPROXIMATELY 3.5 TO 4.0 PERCENT","* BIO RAD - FOR 2018, CONTINUES TO ANTICIPATE IMPROVED PROFITABILITY WITH A CURRENCY- NEUTRAL GAAP OPERATING MARGIN TARGET OF 10 PERCENT Source text for Eikon: Further company coverage:"
11,https://www.reuters.com/article/brief-bio-rad-laboratories-says-ceo-norm/brief-bio-rad-laboratories-says-ceo-norman-schwartzs-2017-total-compensation-was-5-4-mln-vs-4-9-mln-in-2016-idUSFWN1SB1FK,2018-05-04T20:48:54Z,BRIEF-Bio Rad Laboratories Says CEO Norman Schwartz's 2017 Total Compensation Was $5.4 Mln Vs $4.9 Mln In 2016,May 4 (Reuters) - Bio Rad Laboratories Inc:,* BIO RAD LABORATORIES INC SAYS CEO NORMAN SCHWARTZ'S 2017 TOTAL COMPENSATION WAS $5.4 MILLION VERSUS $4.9 MILLION IN 2016 – SEC FILING Source text: (bit.ly/2KCpD6p) Further company coverage:
